

ASX Announcement

11 March 2025

ReNerve Limited Asian Market Update – NervAlign® Nerve Cuff

Marketing Approval in Thailand & Initial Sales in Hong Kong

Highlights:

- ReNerve has received marketing approval for its NervAlign® Nerve Cuff for use in Thailand.
- The Company will now work with its partners in Thailand to launch the product in the region.
- ReNerve has received an initial stocking order from a hospital in Hong Kong – its first purchase from a hospital in the area.

ReNerve Limited (ASX:RNV) (“ReNerve” or “the Company”), an Australian biotechnology company developing novel peripheral nerve repair products, is pleased to announce that it has received marketing approval for its NervAlign® Nerve Cuff product in Thailand. ReNerve will now work with its local partner to launch the product in Thailand, which has a total population of over 70 million people and is popular for medical tourism.

ReNerve has also recently received an initial stocking order for the NervAlign® Nerve Cuff from its first hospital customer in Hong Kong. This will be an important first use in the region of the product, which is ideal for treating transection, compression, and stump neuroma PNI's.

Commenting on the approval in Thailand, ReNerve CEO, Dr Julian Chick, stated: *“The approval in Thailand is another step forward in the development of ReNerve’s operations in Asia and our plans to expand beyond the US. The initial order in Hong Kong is a significant milestone in that market and will serve as a reference for ongoing sales in the region.”*

The NervAlign® Nerve Cuff

ReNerve’s NervAlign® Nerve Cuff product is designed for the protection of repaired nerves and the regeneration of nerves during the healing process after PNI. The product is unique as it protects the nerve while healing, but is also naturally absorbed within 6 months, leaving only regenerated repaired tissue. The medical properties of the NervAlign® Nerve Cuff make it appropriate for a range of different types of surgeries including plastic surgery. Thailand is a destination that is known for medical tourism, with plastic surgery being one of the leading reasons that prospective patients travel there.

The NervAlign® Nerve Cuff has been used for a broad range of reconstructive and nerve repair surgeries, including where nerve injury has occurred, or where nerve protection and regeneration is required during the healing process. The NervAlign® Nerve Cuff has been used by surgeons in breast augmentation and reconstructions, gender reassignment surgeries, as well as trauma and reconstructive surgery and revision surgeries in extremities.

This announcement has been approved for release by the Company’s Board of Directors.



+61 (03) 9482 3940



157 Heidelberg Rd,
Northcote, VIC 3070



www.renerve.com.au

- ENDS -

For further information and enquiries, please contact:

Dr Julian Chick

CEO & Managing Director

ReNerve Ltd

+61 (03) 9482 3940

info@renerve.com.au

Jane Morgan

Investor & Media Relations

Jane Morgan Management

+61 (0) 405 555 618

info@janemorganmanagement.com.au

About ReNerve Limited

ReNerve Limited (ASX:RNV) is a medical device company specialising in advanced nerve repair and regeneration solutions. The Company is focused on commercialising cutting-edge medical devices and tissue-engineering products that seek to address significant unmet needs for patients with peripheral nerve damage – a critical gap in healthcare. ReNerve aims to improve patient outcomes through scientifically backed products that have been developed to enhance the human body's natural healing process, while commercialising cutting-edge, scalable products for the healthcare market. ReNerve wishes to acknowledge AusIndustry's Accelerating Commercialisation program for its support through many of the activities required to commercialise the NervAlign® Nerve Cuff.